Interesting development.....would have to think this is to fund progress of BTX 1204 through phase II clinical trials (most likely?). After all they are fully funded for the full phase II over BTX 1503.....and 1204 was leading the pack in the AD treatment space when they finished off the 1b trials recently......
"Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation".
Could relate to this......."A further Phase 1b BTX 1308 psoriasis patient study is also scheduled to commence in 3Q CY2018".
We'll know soon enough.
Interesting development.....would have to think this is to fund...
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |